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Running title: Acute Endovascular Reperfusion Treatment in Ischemic Stroke in Denmark 
2011-17 
 
Abstract 
Background: Acute endovascular reperfusion treatment (aERT) of stroke patients with large 
vessel occlusions (LVO) is efficacious and safe according to several clinical trials. Data on 
outcome and safety of aERT in daily clinical routine is warranted, and in this study we 
present national data from Denmark 2011 -2017. 
 
Methods: National data for Denmark from 2011 through 2017 on all aERT procedures in 
patients with acute ischemic stroke and CTA/MRA verified LVO. Data were derived from 
the Danish Stroke Registry (DRS), a national clinical quality registry to which reporting is 
mandatory for all hospitals treating stroke patients. Outcome (mRS) after 3 months, including 
time of death, was assessed prospectively based on clinical examination or the Danish Civil 
Registration System (DCRS). 
Results: During the 7 years of observation a total of 1,720 patients were treated with aERT. 
The annual number of procedures increased from 128 in 2011 to 409 in 2017. The median 
age was 68 years, 58% were males, and median NIHSS at baseline was 16. Median time from 
symptoms onset to groin puncture was 238 minutes with a decreasing trend during the years. 
Successful recanalisation was reported in 1,306 (76%) of patients. At 3-months follow-up 
mRS 0-2 was reported in 46% whereas 14% of patients had died.  
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Conclusions: Routine data on aERT in acute ischemic stroke in Denmark from 2011-17 
suggest that the procedure is safe and efficacious.  
 
Introduction 
Results from clinical trials favouring mechanical endovascular reperfusion treatment (ERT) 
versus best medical treatment alone 
1-5
 have substantially changed the acute treatment in 
patient with ischemic stroke and large vessel occlusion (LVO). Following the positive trial-
results data from only few and relatively small study populations have suggested that “real-
life” data may provide results similar or even better than those reported from the trials 
6-8
. 
The present study is the first to present national results on outcome after aERT. Even before 
results from the aERT trials became publically available 3 centers in Denmark  treated 
patients with acute ischemic stroke and confirmed LVO . Data were collected prospectively 
as part of the mandatory Danish Stroke Registry 
9
 allowing us to present national data on 
patient presentation, time to treatment, and functional outcome covering the years 2011 
through 2017.  
 
Methods  
Population 
Acute ERT was provided at three university hospitals in Denmark (Copenhagen University 
Hospital Rigshospitalet, South Denmark University Odense Hospital, and Aarhus University 
Hospital), thereby covering the entire Danish population (5.6 million inhabitants). The three 
sites were fully equipped for aERT 24 hours a day, 7 days a week. Two of the sites, Aarhus 
and Odense, were primary health facilities for routine thrombolysis in acute ischemic stroke, 
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whereas the Copenhagen hospital site only provided acute thrombolysis to already locally 
admitted patients.     
All patients with a suspected acute ischemic stroke were referred acutely to the nearest  
specialized stroke center and evaluated for acute treatment with IV alteplase treatment (IVT);  
alteplase administration within 4½ hours after stroke symptoms onset 
10
  was applied 
nationally throughout the study years.  
 
Diagnosis of ischemic stroke was based on clinical symptoms of acute neurological deficits 
and acute CT/MR excluding intracerebral hemorrhage as the underlying cause of stroke 
symptoms. Patients with clinically suspected large vessel occlusion were examined with CT-
angiography (CTA) or MR-angiography (MRA).    
 
The criteria for aERT were agreed upon in a national expert group representing all 5 regions 
of Denmark in 2010 
11
. All patients had a standard non-enhanced cranial computed 
tomography (CT) or magnetic resonance imaging (MRI) and a CTA or MRA. Treatment 
decision was based on review of all images performed by a vascular neurologist and 
interventional neuroradiologist. There was no upper age limit, but relative contra indications 
for aERT included a pre-stroke mRS of 3 or greater and co-morbidities that could increase 
risk of complications during the procedure. The NIHSS should be 10 or higher and the infarct 
volume less than 1/3 of the MCA territory (clinical-imaging mismatch assessment). Time 
from stroke symptoms onset to start of aERT should be no longer than 6 hours in the anterior 
circulation but up to 12 hours for occlusion in the posterior circulation. It was not required to 
assess the Alberta Stroke Program Early CT Score (ASPECTS) or use specialized soft-ware 
for estimating infarct volume.  
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Inter-hospital patient transfer was requested for immediate transport to the ERT center in 
ambulances or helicopter and treatment with alteplase was continued during transportation 
(drip and ship).  
On arrival, the patient’s neurological impairments were assessed by the vascular neurologist,   
and together with the neuro-interventionalist decided on whether the patient should have 
acute diagnostic subtractions angiography, or whether the patients should have an additional 
CT or MR examination (typically in situations where the patient had recovered clinically to a 
score of <8 on the National Institute of Health Stroke Scale (NIHSS), or if the neurological 
symptoms indicated severe stroke with impaired brain stem functions.  
 
Endovascular thrombectomy was performed with the use of different devices including stent 
retrievers and aspiration catheters using manual aspiration or aspiration with pump at the 
decision of the treating neuro-interventionalis (devices used included Solitaire stent, 
EmboTrap, ERIC, pReset, Capture). Mechanical treatment could include thrombus aspiration, 
retraction or disruption of the thrombus with wire and percutaneous transluminal angioplasty 
or stenting of acute occlusion or tight stenosis of internal carotids. Choice of  anesthesia 
during the procedure was based on a combined evaluation by the vascular neurologist, neuro-
radiologist, and anesthesiologist considering patient compliance, expected complexity of the 
procedure, duration, and over-all medical status of the patient. Peri- and post-procedural 
administration of fibrinolytic compounds, platelets inhibitors, or anti-coagulation therapy was 
based on an individual assessment made by the endovascular team and according to best 
medical practice at the time of treatment.   
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Study Variables 
Demographic, clinical, neuroimaging, and outcome data were recorded prospectively, 
including the patients baseline characteristics, NIHSS score on admission, results of 
neuroimaging data (CT/MRI/CTA/MRA), time elapsed from stroke onset to first hospital 
arrival and to arrival at ERT hospital, treatment or not with IV alteplase, indication for ERT 
and  results of recanalization using the modified thrombolysis in cerebral infarction (mTICI) 
where 0 = no perfusion, 1 = perfusion past the initial obstruction but limited distal branch 
filling with little or slow distal perfusion, 2a = perfusion of less than half of the vascular 
distribution of the occluded artery, 2b = perfusion of half or greater of the vascular 
distribution of the occluded artery, 3 = full perfusion with filling of all distal branches  
12
.      
 
Clinical outcome at 3 months after the aERT procedure was assessed by using the modified 
Rankin Scale Score (mRS) 
13
 by a trained member of the neurovascular outpatient clinic 
(unblinded). The  assessment was based on prospective clinical examination or telephone 
interview, and in few cases based on patient files or the Danish Civil Registration System 
(DCRS). . The  DCRS where all inhabitants have a unique identification number  enabled 
complete follow-up of all Danish patients with regards to vital status until 1 year after the 
ERT procedure. Only patients who were discharged or died before January 1
st
 2017 were 
included in the 3 months mRS and 1 year survival analyses. 
 
In subgroup analyses we applied retrospectively key inclusion criteria from the MRCLEAN 
study to our study population including age ≥18 years, baseline NIHSS≥2, time from 
symptom onset to groin puncture <6 hours, occlusion in distal intracranial carotid artery or 
middle/anterior (M1/M2/A1/A2) cerebral artery. 
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Data Analysis 
Data on all patients who had had groin puncture were included in the database and included 
in the analyses.   
 
The data are expressed as median and interquartile range (IQR), mean ± standard deviation 
(SD) for continuous variables, and as absolute and relative frequencies for categorical 
variables. When necessary, comparisons between groups on clinical outcomes were made 
using Chi χ2 test for categorical variables. Comparison of 3 months mRS outcome in the 
MRCLEAN trial with our data was tested by using unadjusted common odds ratio (OR) 
reported with 95% confidence interval (95 % CI) to indicate statistical precision. Statistical 
significance was set at P<0.05 for test of all hypothesis. Comparison with data from the 
MRCLEAN trial was against the intervention group only.  
 
Results 
A total of 1,720 patients were treated with aERT during the 7 years of observation from 2011 
to 2017, table 1. The median age was 68 years and the total of 993 male patients  constituted 
58%. The median NIHSS score at baseline was 16 during all years and ranged from 0 to 38. 
A total of 1,180 (69%) of patients were treated with IV alteplase prior to the ERT procedure, 
but the proportion decreased from 78% in 2011 to 58% in 2017. 
 
The median time from stroke onset to arrival at the initial hospital remained stable at 
approximately 85 minutes with little variation between each year, table 1. The median time 
from  arrival at the first hospital to the angio-suite decreased from 147 minutes in 2011 to 89 
minutes in 2017. Analyses for each of the EVT-centers varied with a  median delay of 1115 
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minutes for Rigshospitalet, Copenhagen, whereas it was 89 and 95 minutes for the centers in 
Aarhus and Odense, respectively.   
 
Approximately two-thirds of vessel occlusions were in the anterior circulation, whereas 
vessel occlusions in the posterior circulation included a basilar artery occlusion in 182 (8 %), 
vertebral artery in 48 (2%), and posterior cerebral artery /other in 55 (2%). The distribution of 
site of vessel occlusions in patients remained stable throughout the observation period. 
Stenting was done in 259 (15%) patients during the observation period.    
 
3-months mRS outcome and 1 year survival    
There were 1,311 (76%) patients who were discharged before January 1
st
, 2017, and of these 
there were 596 (46%) patients who had a 3-months mRS score of 0 – 2 and 187 (14%) had 
died, table 2. In 157 (15%) patients there were missing information from the 3-months 
follow-up.  
 
There were 994 (76 %) patients who survived beyond the first year after the aERT procedure 
while 284 (22%) had died. Data on vital status was missing for 33 (3%) patients who were 
not residing in Denmark. One-year fatality decreased during the observation period from 23% 
in patients treated in 2011 to 18% for those treated during 2016 but not statistically 
significant (RR 0.95, 95% confidence interval (CI): 0.85-1.10).  
 
There were 156 (9%) patients with posterior circulation (BA or VA) who were discharged 
before January 1
st
, 2017. Of these, there were 66 (42%) with a 3 months mRS 0-2 whereas 36 
(23%) had died. Their 1-year survival 100 (64%) whereas 52 (33%) had died and there were 
missing information in 4 (3%).     
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In the sub-sample of patients stented during the aERT, 210 of these patients were discharged 
before January 1
st
, 2017, and a mRS of 0-2 was reported in 116 (55%) whereas 17 (8%) had 
died. 
 
Recanalisation 
Complete recanalisation, TICI 3, was reported in 791 (46%) of patients, whereas 
recanalisation was TICI 2a in 71 (4%) patients and TICI 2b in 515 (30%) patients. Overall 
successful recanalization (TICI 2b-3) was reported in 1,306 (76 %) of patients. There were 
215 (13%) with a reported TICI 0, and missing data from 92 (5%) of treated patients.    
 
Safety 
Peri-procedural vessel perforation was reported in 49 (3%) patients, and subarahnoid 
hemorrhage and ICH was reported in31 (2%) and 14 (<1%), respectively. New embolisation 
during the aERT procedure was registered in 96 (6%) of patients. Vessel dissection was 
reported in 18 (1%).   
 
Peri-procedural vessel perforation in the posterior circulation was reported in 8 (4%), and 
subarchnoid hemorrhage and ICH was reported in 6 (3%), and 1 (<1%), respectively. In these 
patients new embolisation was registered in 10 (5%), whereas vessel dissection was reported 
in 5 (3%).  
 
In the sub-sample of patients treated with stenting (n=259) the occurrence of peri-procedural 
vessel perforation was reported in 9 (3%) patients, and subarahnoid hemorrhage and ICH was 
reported in 4 (2%) and 2 (<1%), respectively. New embolisation during the aERT procedure 
was registered in 15 (6%) of patients and vessel dissection was reported in 4 (2%).   
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Comparison with MRCLEAN  
Baseline characteristics of 870 Danish aERT patients meeting key inclusion criteria used in 
the MRCLEAN study 
1
 were compared with the intervention group in the trial, table 3. 
Median age, baseline NIHSS, proportion of patients treated with alteplase, and the proportion 
of male patients were similar between the two populations.  The delay from stroke onset to 
groin puncture was almost an hour longer in the MRCLEAN trial compared with the 
aggregate Danish data. In both cohorts two-out-of-three patients had MCA-M1 occlusion, but 
there were more patients in the trial with ICA and ICA-tandem occlusions, and more patients 
with MCA-M2 and anterior occlusion among the Danish patients. Successful recanalisation 
(TICI 2b-3) was reported in 686 (79%) patients while in the MRCLEAN trial successful 
recanalisation was reported in 59% of patients (RR 1.34, 95%CI:1.19-1.52).     
 
There were 658 patients discharged before January 1
st
, 2017, and 334 (52%) patients who had 
a 3 months mRS score 0-2; the proportion of patients who at 3 months had a mRS score 0-2 
in MRCLEAN was 33 % (RR 1.56, 95%CI:1.28-1.90). A total of 86 (13%) of the Danish 
patients had died at 3 months compared to 21 % of the patients in the MRCLEAN 
intervention group (RR 0.62, 95%CI: 0.45-0.85). 
 
Discussion 
In this nationwide study the number of patients in Denmark with cerebral LVO who received 
aERT increased markedly during 2011 – 2017. In treated patients discharged before January 
1
st
 2017, the 3 months mRS score was 0-2 in 46% whereas 14% had died. In a sub-sample of 
patients with basilar or vertebral occlusion 42% had 3 months mRS 0-2 whereas 23% died. 
Comparison of patients meeting key criteria in the MRCLEAN trial showed 3-months 
outcome and 1-year survival rates comparable to or better than reported in MRCLEAN.  
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The median delay from stroke symptoms onset to arrival at the first hospital was stable 
throughout the observation period around 85 minutes suggesting  good awareness regarding 
stroke symptoms 
14
,  and that fast treatment is a priority within the emergency medical 
services  
15
.  However, there was a delay of  1½- 2 hours from time of arrival at the first 
hospital to arrival at the angio-suite although improving  especially in 2016 and 2017 
following the positive trials. Inter-hospital transportation must be improved as time to 
recanalization is an important prognostic factor for aERT patients
16-17
.  
 
National provision of aERT at few centers may increase transportation time, but could also 
ensure high volume of patients; staff experience is a recognized important factor for a good 
outcome 
18
. The high proportion of patients with a successful recanalisation and low overall 
mortality indicates an overall good quality of care throughout the treatment phase; it remains 
unknown whether this result is due to differences in staff experience, use and selection of 
mechanical retrievers, patient selection, type of anesthesia, or other factors. 
  
In this study median delay was 20 minutes longer to the ERT center not providing routine IV 
alteplase. Differences  in stroke center set-up are a likely contributing factor for the delay, but 
case-mix and patient selection might also impact.  
 
Our results are consistent with observations from other European studies on outcome after 
aERT in patients with cerebral LVO. In a single-center study from Portugal including 77 
patients, 65% achieved a 3 months mRS of 0-2 while 12% of treated patients had died 
6
. A 
German study of 97 patients treated with mechanical intervention, there were 40 (41.2%) 
with a 3 months mRS of 0-2 while 24.7% died 
7
. A Belgium register of 85 patients reported a 
3 months mRS 0-2 in 42% of patients but with a mortality of 26%, with a higher mortality in 
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patients with occlusions in the posterior circulation 
8
. In our sample patients with posterior 
circulation vessel occlusion had a 3 months mRS 0-2 comparable to patient with occlusion in 
the anterior circulation, but as in the Belgium study, we also showed that the 3 months 
mortality was markedly higher. The 2 years follow-up of the MRCLEAN population 
suggested that the beneficial outcome is sustained if treated with mechanical intervention, 
and that fatalities occur mainly in the initial phase 
19
. In our population fatalities within the 
first 3 months remained stable around 15% whereas the one-year mortality decreased from 
23% to 18% (table 2).  
 
The present study has several advantages as we have included all patients treated in Denmark 
during the 7 years of observation. The three participating sites used the same reporting form, 
which  was completed during patient treatment and as part of routine and mandatory data 
collection for the Danish Stroke Registry.  Data administration was provided nationally by an 
independent  organisation, including preparation of analyses for the present study. Due to the 
unique personal identification number we have complete vital follow-up for all patients, and 
missing information pertains only to 33 patients not residing in Denmark.  All IV-alteplase 
and aERT procedures were provided with no direct costs for the patients at public hospitals 
only.     
 
This study also has several limitations such as the 3-months assessment of functional status 
was not blinded, which could introduce observer bias. However, the mortality was 
significantly lower in the Danish population compared to MRCLEAN despite similar 
baseline characteristics in the two populations. Even if all patients with missing vital 
information were deemed fatal events , the fatality would remain lower among the Danish 
patients than in the MR-CLEAN trial. The neuro-interventionalists self-reported the site of 
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vessel occlusion and TICI score immediately after each procedure, but without  formal 
review of the correctness of these data and no adjudication. . Whereas the proportion of 
patient with MCA-M1 occlusions was similar, more patients had ICA and ICA-tandem 
occlusion in the MR CLEAN trial; an imbalance which could impact the overall prognosis. 
Our decision to compare with data from the MR CLEAN trial was due to that this trial was 
based on basic clinical selection criteria as in our register; comparison of our data with other 
aERT trials relying on more sophisticated selection criteria could provide different 
conclusions.  
 
In conclusion, the present study suggests that aERT of patients with large vessel occlusions 
was performed efficacious and safe during 2011-2017 in Denmark. Comparisons of the 3-
months mRS outcome and 1-year survival rate with the intervention group in the MR 
CLEAN study suggested that routine real-life use of aERT procedures have resulted in 
similar or even better outcomes.     
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Table 1: Baseline Characteristics of Patients Treated with Acute Endovascular Reperfusion Treatment, Denmark 2011-
2017 
   2011 2012 2013 2014 2015 2016 2017 2011-17 
   (N=126) (N=198) (N=201) (N=202) (N=275) (N=309) (N=409) (N=1,720) 
Age – yr (median)  63 68 60 67 68 68 70 68 
Male sex – no (%)  71 (56) 129 (65) 110 (55) 120 (59) 152 (55) 169 (55) 242 (59) 993 (58) 
NIHSS score baseline (median) 15 16 16 16 16 16 15 16  
- Range   1-38 0-36 0-36 0-36 0-35 0-36 0-38
 0-38 
- missing -no (%)  27 (21) 48 (24) 46 (23) 59 (29) 79 (29) 77 (25) 83 (20) 419 (24) 
Treatment with IV alteplase – no (%) 98 (78) 146 (74) 143 (71) 133 (66) 195 (71) 227 (73) 238 (58) 1,180 (69) 
Time from stroke onset to arrival 1.hospital 
 Median, minutes 80 94 94 89 78 87 87 87 
 IQR  57-151 60-150 60-151 56-166 51-147 50-155 55-160 55-154 
 Missing data (%) 18 (14) 22 (11) 23 (12) 13 (6) 33 (12) 16 (5) 10 (2) 135 (8) 
Time from arrival 1st hospital to angio-suite 
 Median, minutes 147 105 90 120 116 96 89 104  
 IQR  94-207 70-169 66-160 68-175 64-182 55-145       59-143 63-165 
 Missing data (%) 29 (23) 28 (14) 31 (15) 23 (11) 38 (14) 20 (6) 11(3) 180 (10) 
Time from arrival at angio-suite to groin puncture 
 Median, minutes 39 37 30 30 28 25              23  25 
 IQR  20-40 25-41 20-35 18-34 19-34 17-30 15-29 18-34 
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 Missing data (%) 38 (30) 20 (10) 16 (8) 12 (6) 14 (5) 14 (5)     14(3) 128 (8) 
Time from stroke onset to groin puncture 
 Median, minutes 291 286 272 309 292 256 279 238 
 IQR  198-335 204-313 186-320 195-345 175-335 164-334     170-317 178-321 
Missing data (%) 47 (37) 30 (15) 29 (14) 15 (7) 14 (5) 14 (5)                  19(5) 168 (10) 
Site of arterial occlusions – no (%) 
 CCA   1 (1) 0 (0) 3 (1) 1 (1) 2 (1)    3 (1) 2 (1) 12 (1) 
ICA  26 (17) 48 (19) 37 (13) 41 (14) 60 (16) 62 (15) 71 (15) 345 (15) 
ICA-T  7 (5) 26 (10) 25 (9) 30 (10) 40 (11) 46 (11) 52 (11) 226 (10) 
M1   43 (29) 103 (41) 125 (45) 109 (38) 134 (36)  172 (40) 185 (38) 871 (39) 
M2  13 (9) 38 (15) 32 (12) 36 (13) 68 (18) 79 (19) 81 (17) 347 (15) 
A1 or A2  4 (3)   3 (1) 6 (2) 9 (3) 10 (3)   10 (2)   8 (2) 50 (2) 
VA  1 (1)   6 (2) 8 (3) 11 (4) 6 (2)   8 (2) 8 (2) 48 (2) 
BA  11 (7) 16 (6) 26 (9) 31 (11) 37 (10) 27 (6) 34 (7) 182 (8) 
PCA/other  4 (3) 5 (2) 5 (2) 12 (4) 9 (2) 10 (2) 10 (2) 55 (2) 
Missing information 40 (27) 4 (2) 8 (3) 8 (3) 9 (2) 9 (2) 32 (7) 110 (5)  
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Table 2: 3-Months and 1-year Outcome in Patients Treated with Acute Endovascular Reperfusion Treatment, discharged 
2011-2016, Denmark 
2011 2012 2013 2014 2015 2016  2011-16  
   (N=126) (N=198) (N=201) (N=202) (N=275) (N=309) (1,311) 
3-months mRS, No (%) 
 0  13 (10) 16 (8) 19 (9) 10 (5) 28 (10)  34 (11) 120 (9) 
 1  20 (16) 38 (19) 38 (19) 32 (16) 56 (20) 59 (19) 243 (19) 
 2  17 (13) 31 (16) 27 (13) 33 (16) 33 (12) 36 (12) 233 (18) 
 3  13 (10) 19 (10) 21 (10) 18 (9) 29 (11)  27 (9) 127 (10) 
 4  14 (11) 27 (14) 31 (15) 35 (17) 55 (20) 68 (22) 174 (13) 
 5  12 (10) 10   (5) 7 (3) 10 (5) 13 (5)   18 (6) 70 (5) 
 6  17 (13) 32 (16) 20 (10) 24 (12) 48 (17)  46 (15) 187 (14) 
Missing  20 (16) 25 (13) 38 (18) 40 (20) 13 (5)  21 (7) 157 (12) 
1 year survival   2011 2012 2013 2014 2015 2016 2011-16 
 Alive  96 (76) 147 (74) 155 (77) 146 (72) 214 (78) 236 (76) 994 (76) 
 Deceased  29 (23) 48 (24) 44 (22) 50 (25) 56 (20) 57 (18) 284 (22) 
 Missing  1 (1) 3 (2) 2 (1) 6 (3) 5 (2) 16 (5) 33 (3) 
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Table 3: Baseline characteristics of ERT patients Denmark 2011-2017 Complying with Key MR-CLEAN Criteria 
   2011-17 MR-CLEAN     
(N=870) (n= 233) 
Age – yr (median)  71 66 
Male sex – no (%)  293 (57) 135 (58) 
NIHSS score baseline (median) 17 17 
- Range   2-29 3-30 
- missing -no (%)  0 (0) NA 
Treatment with IV alteplase – no (%) 756 (87) 203 (87) 
Time from stroke onset to arrival 1.hospital 
 Median, minutes 79 76   
 IQR  49-110 50-111 
 Missing data (%) 24 (3) 37 (7)  
Time from arrival 1st hospital to angio-suite 
 Median, minutes 103 100  
 IQR  61-155 67-153 
 Missing data (%) 11 (8) 44 (9) 
Time from arrival at angio-suite to groin puncture 
 Median, minutes 25 27 
 IQR  19-33 20-35 
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 Missing data (%) 8 (6) 26 (5) 
Time from stroke onset to groin puncture 
 Median, minutes 213 260 
 IQR  1168-265 210-313 
Missing data (%) 0 (0) 29 (6)  
Site of arterial occlusion – no (%) 
 CCA      8 (1)     0 
ICA  221 (19)  76 (33) * 
ICA-T  142 (12)  59 (25) * 
M1  527 (46) 154 (66)  
M2  224 (20)  18 (8) * 
A1 or A2  31 (3)    1 (1) *     
Legend: * indicates statistically significant difference with P <0.05, between DK 2011-17 versus MR CLEAN intervention group. 
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Table 4: 3-months mRS and 1 year survival in ERT patients, Denmark (discharged 2011-2016), and MR-CLEAN criteria 
   2011-16 MR-CLEAN  
   (N=658) (n=233) 
3-months mRS 
 0  61 (9)   7 (3)  
 1  145 (22) 21 (9) 
 2  138 (21) 49 (21) 
 3  65 (10) 42 (18)  
 4  98 (15) 51 (22) 
 5  37 (6) 14 (6) 
 6  86 (13) 49 (21) 
 Missing  28 (4) NA 
1 year survival  2011-16  
 Alive  532 (81) NA 
 Deceased  116 (18) NA 
 Missing    10   (2 
